Skip to main content

Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL)

Indian Journal of Hematology and Blood Transfusion volume 36, pages 51–58 (2020)Cite this article

Abstract

Methotrexate (MTX) is an extensively prescribed antimetabolite especially in the treatment of several pediatric cancers, though managing toxicities associated with methotrexate in high dose continues to be a challenge. A prospective study was carried out from April 2017 to October 2018. Children of either sex below 18 years at the time of enrolment and receiving high dose Methotrexate intravenous infusion over 24 h as a 2 g/m2, 3 g/m2 and 5 g/m2 dose was included in the study. The serum methotrexate level was estimated after the start of 48 h HDMTX infusion by using the ARCHITECT methotrexate assay. Toxicity due to HDMTX was assessed by Common Terminology Criteria for Adverse Events v.5.0. A total of 244 HDMTX infusions were delivered to 62 ALL patients. From the total of 244 cycles, serum methotrexate level in 35 cycles after the start of 48 h HDMTX infusion was found to be ≥ 1.0 μmol/L with reported toxicities among 31 cycles (88.6%). In 209 cycles MTX level was found to be less than 1.0 is statistically significant as compared to other cycles (p < 0.0001). Highest toxicities reported were in cycle I (38.8%). The toxicities such as oral mucositis, neutropenia, the elevation of liver enzymes, dermatological toxicities were found more in cycles whose methotrexate level are greater than 1.0 μmol/L. Dose reduction, increased the length of stay and treatment delay occurred in patients with severe toxicities. Severe toxicities of methotrexate can be interrelated with serum methotrexate levels at 48 h after the start of HDMTX infusion.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD (2016) Preventing and managing toxicities of high-dose methotrexate. Oncologist 21:1471–1482

    CAS  Article  Google Scholar 

  2. Abramson JS, Hellmann M, Barnes JA et al (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:4283–4290

    Article  Google Scholar 

  3. Kataria P, Kendre P, Patel A, Tahiliani N, Ikhar S (2018) Methotrexate-induced toxic epidermal necrolysis: a rare case report and review of literature. Indian J Crit Care Med 22:740–742

    CAS  Article  Google Scholar 

  4. Ferreri AJ, Guerra E, Regazzi M et al (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 90:353–358

    CAS  Article  Google Scholar 

  5. Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694–703

    CAS  Article  Google Scholar 

  6. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2017) Common terminology criteria for adverse events (CTCAE), available via DIALOG https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 2 Jan 2019

  7. Pui CH, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166–178

    CAS  Article  Google Scholar 

  8. Pui CH, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. N Engl J Med 350:1535–1548

    CAS  Article  Google Scholar 

  9. Jackson N, Menon BS, Zarina W, Zawawi N, Naing NN (1999) Why is acute leukemia more common inmales? A possiblesex-determined risk linked to the ABO blood group genes. Ann Hematol 78:233–236

    CAS  Article  Google Scholar 

  10. Hewitt M, Weiner SL, Simone JV, The epidemiology of childhood cancer (2003) Childhood cancer survivorship: improving care and quality of life, 1st edn. The National Academies Press, Washington, pp 20–36

    Google Scholar 

  11. Pui C-H, Yang JJ, Hunger SP, Pieters R, Schrappe M, Biondi A et al (2015) Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol 33:2938–2948

    CAS  Article  Google Scholar 

  12. Mantadakis E, Cole PD, Kamen BA (2005) High dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use? Pharmacotherapy 25:748–755

    CAS  Article  Google Scholar 

  13. Liu Y, Xu Y, Lin N, Jiang S, Wang Y, Ye Z (2015) High-dose methotrexate (HD-MTX) used as an adjunct with other chemotherapeutics for the treatment of osteosarcoma. Cell Biochem Biophys 71:1097–1104

    CAS  Article  Google Scholar 

  14. Treon SP, Chabner BA (1996) Concepts in use of high-dose methotrexate therapy. Clin Chem 42:1322–1329

    CAS  Article  Google Scholar 

  15. Camitta B, Mahoney D, Leventhal B et al (1994) Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group Study. J Clin Oncol 12:1383–1389

    CAS  Article  Google Scholar 

  16. Boussios S, Pentheroudakis G, Katsanos K, Pavlidis N (2012) Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol 25:106–118

    PubMed  PubMed Central  Google Scholar 

  17. Pico JL, Avila-Garavito A, Naccache P (1998) Mucositis: its occurrence, consequences, and treatment in theoncology setting. Oncologist 3:446–451

    CAS  Article  Google Scholar 

  18. Mahmoud LB et al (2018) Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia. Adv Clin Exp Med 27:1061–1068

    Article  Google Scholar 

  19. Widemanna BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11:694–703

    Article  Google Scholar 

  20. Jaseb K, Ghaedi E, Shahin M, Mirmohamadkhani M, Javadian P, Haghi S (2018) Renal function as a predicting model for plasma methotrexate concentration after high-dosemethotrexate chemotherapy in pediatric malignancy. J Nephropharmacol 7:74–79

    CAS  Article  Google Scholar 

  21. Kapoor G, Sinha R, Abedin S (2012) Experience with high dose methotrexate therapy in childhood acutelymphoblastic leukemia in a tertiary care cancer centre of a developing country. Pediatr Blood Cancer 59:448–453

    Article  Google Scholar 

  22. Özdemir ZC, Turhan AB, Kar YD, Bör Ö (2016) The frequency ofhepatotoxicity and myelotoxicity in leukemic children with different high doses of methotrexate. Int J Pediatr Adolesc Med 3:162–168

    Article  Google Scholar 

  23. Ramamoorthy SK, Hephziba R (2013) Acute renal failure post high dose methotrexate infusion successfully managed with high dose folinic acid and high flux dialysis. Indian J Hematol Blood Transfus 29:90–92

    Article  Google Scholar 

  24. Holmboe L, Andersen AM, Morkrid L, Slordal L, Hall KS (2012) High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcomapatients. Br J Clin Pharmacol 73:106–114

    CAS  Article  Google Scholar 

  25. Ferdousi S, Akhter A, Nahar K, Islam A (2017) High dose methotrexate and leucovorin rescue therapy in childhood malignancies: experience in resource-limited country. Bangladesh J Child Health 41:15–23

    Article  Google Scholar 

Download references

Acknowledgements

We would like to thanks all the staff of Pediatric Oncology Department of Bharati and KEM Hospital and Research Center, Pune for the completion of the study.

Author information

Affiliations

  1. Department of Clinical Pharmacy, Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Pune, Maharashtra, India

    Manjusha Sajith & Atmaram Pawar

  2. Department of Pediatrics, Paediatric Hemato Oncologist, Bharati Hospital and Research Center, Pune, Maharashtra, India

    Vibha Bafna & Sandip Bartakke

  3. Consultant Hematologist, KEM Hospital and Research Centre, Pune, Maharashtra, India

    Kannan Subramanian

  4. Department of Biochemistry, Bharati Vidyapeeth Medical College and Research Center, Pune, Maharashtra, India

    Neela Vaidya

Authors
  1. Manjusha Sajith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atmaram Pawar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vibha Bafna
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sandip Bartakke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kannan Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Neela Vaidya
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors listed have contributed to the work and agreed to submit the manuscript for publication.

Corresponding author

Correspondence to Manjusha Sajith.

Ethics declarations

Conflict of interest

The authors have no conflict of interests.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee.

Human and Animal Rights

This study used blood sample from ALL patients. Ethical approval was obtained from institutional ethics committee (BVDUMC/IEC/74 and KEMHRC/LFG/EC/2423) to conduct the study.

Informed Consent

Informed consent was obtained from the parents/guardian of study subjects.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sajith, M., Pawar, A., Bafna, V. et al. Serum Methotrexate Level and Side Effects of High Dose Methotrexate Infusion in Pediatric Patients with Acute Lymphoblastic Leukaemia (ALL). Indian J Hematol Blood Transfus 36, 51–58 (2020). https://doi.org/10.1007/s12288-019-01144-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12288-019-01144-3

Keywords

  • High dose methotrexate
  • Serum methotrexate level
  • Toxicities
  • Acute Lymphoblastic Leukaemia